Compounds · Metabolic & weight · Treatment of obesity and type 2 diabetes
Survodutide (BI 456906)
BI 456906, BI456906, Survodutide
A dual glucagon/GLP-1 receptor agonist (BI 456906) from Boehringer Ingelheim and Zealand Pharma. It combines glucagon-driven energy expenditure with GLP-1-driven appetite suppression for weight management and metabolic dysfunction–associated steatohepatitis.
0.3 → 4.8 mg weekly, titrated
Research score 85/100. Reference only, not a prescription.
- Appetite Suppression
- Blood Sugar Control
- Metabolic Enhancement
- GLP-1 Agonist
- Weight Loss
- US status
- Investigational
- Approval
- Phase 2 Clinical Trial
- Evidence
- Phase 3 trials ongoing (SYNCHRONIZE). Strong weight loss and liver fat reduction data.
- Research score
- 85 / 100
- Indication
- Investigational - Type 2 Diabetes Mellitus
- Origin
- Germany
- Source category
- Digestive System
- Status group
- Investigational
Mechanism
GLP-1 receptor activation raises glucose-dependent insulin release, cuts glucagon, slows gastric emptying, and promotes satiety via the hypothalamus; glucagon receptor activation adds energy expenditure and fat oxidation through liver glucose production and thermogenesis; structural modifications extend its half-life.
Safety file
GI effects such as nausea, diarrhea, and vomiting are common and dose-related; some trials saw higher discontinuation due to GI issues.
- Nausea
- Vomiting
- Diarrhea
- Decreased appetite
- Injection site reactions
Reconstitution
| Vial | 1 mL water | 2 mL water |
|---|---|---|
| 10 mg | 10 mg/mL | 5 mg/mL |
- Use bacteriostatic water as the diluent.
- Add the water slowly, letting it run down the inside wall of the vial rather than onto the powder.
- Swirl gently to mix, then leave it to dissolve. Do not shake.
- Give it a few minutes. The finished solution should be clear and colourless.
Protocol
Route: Subcutaneous
Standard titration (once weekly, subcutaneous)
- Start at 0.3 mg once weekly and step up toward a working dose; the phase 2 trial escalated over 20 weeks
- The phase 2 obesity trial topped out at 4.8 mg weekly; phase 3 (SYNCHRONIZE) goes up to 6 mg
- Effects become noticeably stronger from 1.8 mg upward
Where most people land
- 1.8 mg to 4.8 mg weekly is the working range
- Do not skip steps; the glucagon and GLP-1 combination makes a fast ramp rough on the gut
Dosing detail
- Start at 0.3 mg. This is a tolerance dose; real weight effect kicks in around 1.8 mg.
- Step up gradually; the phase 2 trial took 20 weeks to reach the top dose.
- Phase 2 went up to 4.8 mg weekly. Stay at the lowest dose that keeps you progressing.
- One consistent day per week.
Duration
- Titrate over roughly 4 months, then maintain. A plateau after 12 to 16 weeks at your target dose is normal, not failure.
Notes
- A GLP-1 / glucagon dual agonist studied heavily for weight and metabolic effects.
- Inject subcutaneously, rotate sites.
- Nausea and fullness early on, easing as the body adjusts.
Storage and handling
- Keep the powdered (lyophilized) vial in a cool, dark place. Refrigerate it for longer-term storage before mixing.
- Once reconstituted and refrigerated at 2–8 °C away from light, use the vial within 28 days.
- Do not freeze a reconstituted vial, and keep it away from heat and sunlight.
- If the solution turns cloudy, develops floating particles, or shows any other sign of degradation, stop using that vial.